Amylin Pharmaceuticals Inc - Current report filing (8-K)
October 31 2007 - 5:29PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM
8-K
Current
Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 31, 2007
AMYLIN PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
0-19700
|
33-0266089
|
(State or Other
Jurisdiction of Incorporation)
|
(Commission File
Number)
|
(I.R.S. Employer
Identification No.)
|
9360 Towne Centre Drive
San Diego, California 92121
(Address of principal executive offices and zip code)
Registrants telephone number, including area
code:
(858)
552-2200
Check the appropriate box below if the Form 8-K is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (
see
General
Instruction A.2. below):
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CRF
240.13e-4(c))
Item
8.01. Other Events.
On October 31, 2007, Amylin Pharmaceuticals, Inc. issued a press
release announcing the results from a 30-week comparator study of once-weekly
exenatide long-acting release and BYETTA® (exenatide) injection taken twice
daily in patients with type 2 diabetes. A
copy of the press release is attached as Exhibit 99.1 and is incorporated
herein by reference.
Item 9.01. Financial Statements
and Exhibits.
(d)
Exhibits.
Number
|
|
Description
|
99.1
|
|
Press release issued by
Amylin on October 31, 2007.
|
2
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized.
|
AMYLIN PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
Dated: October
31, 2007
|
By:
|
/s/ LLOYD A. ROWLAND
|
|
|
|
Lloyd A. Rowland
|
|
|
Vice President, Governance and
Compliance, and
|
|
|
Secretary
|
|
|
|
|
|
3
EXHIBIT
INDEX
Number
|
|
Description
|
99.1
|
|
Press release issued by
Amylin on October 31, 2007.
|
4
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024